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Trichloroethylene (TCE), tetrachloroethylene
[perchloroethylene (PERC)], and 1,1,1-
trichloroethane [methylchloroform (MC)] are
volatile organic solvents of widespread indus-
trial use. Their release into the environment
occurs during manufacturing processes as well
as with the normal use of these products.
Combinations of the three chemicals have
been frequently identified in contaminated
groundwater in the proximity of production
facilities and/or hazardous waste disposal sites
(Mumtaz et al. 1998). Consequently, human
occupational and/or environmental exposures
to differently constituted mixtures of the sol-
vents are likely to occur (Wu and Schaum
2000). TCE, PERC, and MC are high-pri-
ority chemicals reported by the Agency for
Toxic Substances and Disease Registry
under the Comprehensive Environmental
Response, Compensation, and Liability Act
with “Completed Exposure Pathway”
(ATSDR 1997).
Coexposure to multiple chemicals may
significantly affect the pharmacokinetics of
one or more mixture components and alter
the target tissue dose of the toxic moiety
(Krishnan et al. 1994a, 1994b). The change
in the tissue dosimetry caused by pharmaco-
kinetic interactions depends on the relative
concentrations of the mixture components
and the underlying mechanism of interac-
tion. Competitive metabolic inhibition is
the predominant mechanism of pharmacoki-
netic interaction for exposures to TCE in
combination with other organic solvents
(Andersen et al. 1987; Barton et al. 1995;
Dobrev et al. 2001; El-Masri et al. 1996a,
1996b). Clearance by exhalation and metabo-
lism are the two major routes of elimination
for volatile organics from the body (Andersen
1981), and quantitative changes in any of
those pathways are expected to significantly
affect the chemicals’ pharmacokinetics. In
humans, the metabolic clearance of PERC
and MC is very low (IARC 1999; Monster
1979; Nolan et al. 1984; Reitz et al. 1988,
1996; Ward et al. 1988), and exhalation is
the major route of elimination. Therefore,
metabolic inhibition of MC and PERC
caused by TCE coexposure will have only a
minor impact on the overall kinetic behavior
of these two compounds. TCE, on the other
hand, is a highly cleared compound with tox-
icities clearly associated with its biotransfor-
mation (Gargas et al. 1990; Lash et al. 2000).
Thus, the main focus of our study was to
quantitatively assess the magnitude of phar-
macokinetic changes in TCE pharmacokinet-
ics due to the presence of the other two
solvents in chemical mixtures.
The assessment of both acute and long-
term occupational exposures to chemical mix-
tures containing TCE requires two different
approaches. The major acute effect of TCE is
on the central nervous system, and neurotoxic
effects such as headaches, sleepiness, fatigue,
and/or drowsiness occur at concentrations of
approximately 100 ppm (Barton and Clewell
2000; Barton and Das 1996). Drowsiness
may be caused by TCE itself and/or
trichloroethanol (TCOH), a metabolite with
a known sedative effect. Because both TCE
and TCOH rapidly equilibrate with the
highly perfused lipid-rich brain tissue, peak
arterial blood TCE concentration (usually at
the end of the exposure period) is a more
appropriate dose metric for drowsiness and
the sedative effects of TCE. The American
Conference of Governmental Industrial
Hygienists established a threshold limit value
(TLV) of 50 ppm, intended to protect against
fatigue, headache, and irritability (ACGIH
2000).
Long-term exposures to TCE have been
repeatedly shown to induce several types of
tumors in experimental animals (reviewed in
Barton and Clewell 2000; Bull 2000; Lash et
al. 2000), and all of them appear to be caused
by metabolism-related products. TCE is
metabolized by two metabolic pathways:
cytochrome P450-mediated oxidation and glu-
tathione-S-transferase (GST)-mediated conju-
gation with glutathione (GSH; Figure 1; Lash
et al. 2000). The oxidative metabolism of TCE
leads to formation of a variety of products,
among which chloral hydrate (CHO),
trichloroacetic acid, and dichloroacetic acid are
considered carcinogenic in rodents. The
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Articles
In this study, we integrated our understanding of biochemistry, physiology, and metabolism of
three commonly used organic solvents with computer simulation to present a new approach that we
call “in silico” toxicology. Thus, we developed an interactive physiologically based pharmacokinetic
(PBPK) model to predict the individual kinetics of trichloroethylene (TCE), perchloroethylene
(PERC), and methylchloroform (MC) in humans exposed to differently constituted chemical mix-
tures of the three solvents. Model structure and parameterization originate from the literature. We
calibrated the single-compound PBPK models using published data and described metabolic inter-
actions within the chemical mixture using kinetic constants estimated in rats. The mixture model
was used to explore the general pharmacokinetic proﬁle of two common biomarkers of exposure,
peak TCE blood levels and total amount of TCE metabolites generated, in rats and humans.
Assuming that a 10% change in the biomarkers corresponds to a signiﬁcant health effect, we calcu-
lated interaction thresholds for binary and ternary mixtures of TCE, PERC, and MC. Increases in
the TCE blood levels led to higher availability of the parent compound for glutathione conjugation,
a metabolic pathway associated with kidney toxicity/carcinogenicity. The simulated change in pro-
duction rates of toxic conjugative metabolites exceeded 17% for a corresponding 10% increase in
TCE blood concentration, indicating a nonlinear risk increase due to combined exposures to TCE.
Evaluation of metabolic interactions and their thresholds illustrates a unique application of PBPK
modeling in risk assessment of occupational exposures to chemical mixtures. Key words: chemical
mixtures, computational toxicology, in silico toxicology, interaction thresholds, metabolic interac-
tion, methylchloroform, occupational exposure, PBPK modeling, tetrachloroethylene, trichloroeth-
ylene. Environ Health Perspect 110:1031–1039 (2002). [Online 3 September 2002]
http://ehpnet1.niehs.nih.gov/docs/2002/110p1031-1039dobrev/abstract.htmlTCE–GSH conjugate undergoes further bio-
transformation through a series of peptidases
to form two isomers, S-1,2-dichlorovinylcys-
teine (S-1,2-DCVC) and S-2,2-DCVC,
which are substrates for β-lyase metabolism
to two reactive species, thioketene and
thioaldehyde (Anders and Dekant 1998;
Bruening and Bolt 2000). These latter two
metabolites are believed to be responsible for
the observed nephrotoxicity in rats.
However, the lower level of β-lyase in human
liver in vitro compared with rats suggests a
lower contribution of this pathway in
humans (Green et al. 1997). Moreover, nei-
ther the reactive metabolites themselves nor
their covalent binding products have yet
been identiﬁed. Despite the debate about the
underlying mechanisms of renal tumor for-
mation for TCE and PERC and their rele-
vance for human risk assessment (Barton and
Das 1996; Bogen and Gold 1997; Fisher et
al. 1998), quantitative changes in TCE
metabolism are expected to have a signiﬁcant
impact on the assessment of its overall
chronic toxicity.
Over the last decade, biological monitoring
has been established as a very useful tool for
assessing workers’ exposures to chemicals (Droz
et al. 1989; Jang et al. 1997). Biomarkers of
exposure such as generated metabolites and/or
parent compound blood levels are measures
frequently used to assess past and current
exposures in occupational and environmental
settings. Although not the only source of vari-
ability in the observed biological monitoring
results, metabolic interactions due to mixed
exposures can significantly complicate their
interpretation (Jang et al. 1999a). Coexposure
to another chemical can either increase or
decrease the biomarker levels (compared with
single exposure) by altering metabolism
and/or elimination. Knowledge about the
magnitude and direction of such changes is
essential for correct interpretation of the
observed biological levels. This article is an
enhancement of the current understanding
about biological monitoring of occupational
exposures to TCE and illustrates the useful-
ness of physiologically based pharmacokinetic
(PBPK) modeling to account for metabolic
interactions in assessment of biological moni-
toring data. Such information may be used to
suggest biological limit values (BLVs) for
mixed exposures.
Previous animal studies from our labora-
tory indicated that simultaneous exposures to
TCE, PERC, and MC within their current
TLVs [time-weighted average (TWA)] would
result in elevated TCE blood levels compared
with single chemical exposures (Dobrev et al.
2001). 
To assess the signiﬁcance of these ﬁndings
in humans, we designed a study to enhance
our understanding of the mechanistic basis of
such interactions and of their thresholds and
to support the process of risk assessment of
chemical mixtures. Speciﬁcally, the objectives
of the current work were defined as follows:
a) development of an integrated human
PBPK model to describe the individual phar-
macokinetics of TCE, PERC, and MC in a
ternary mixture for different occupational
exposure scenarios at and below their current
TLV/TWA; b) evaluation of TCE blood con-
centration and total TCE metabolites gener-
ated as appropriate dose metrics for
identifying the occurrence of pharmacokinetic
interactions during combined exposures to
TCE, PERC, and MC in rats and humans; c)
calculation of interaction thresholds (i.e.,
external exposure concentrations resulting in a
preselected level of change in internal tissue
dosimetry) to provide a quantitative measure
of interactions at occupationally relevant set-
tings using model-derived estimates of TCE
blood levels and total TCE metabolites as bio-
markers of exposure; and d) quantitative
assessment of the changes in parent TCE and
its metabolites at the calculated thresholds,
and their implications to the occupational risk
assessment of exposures to chemical mixtures.
Approach and Methods
In this study, we integrated our understanding
of biochemistry, physiology, and metabolic
interactions with computer simulations to
predict the individual kinetics of TCE, PERC,
and MC in humans exposed to constant levels
of differently constituted chemical mixtures of
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Figure 1. Metabolism of TCE. 1,2-DVT, 1,2-dichlorovinylthiol; TCOG, trichloroethanol glucuronide; TCA,
trichloroacetic acid; DCA, dichloroacetic acid.
Figure 2. Ternary-mixture PBPK model representa-
tion for humans. Fat (F), richly perfused (RT), slowly
perfused (ST), and liver (L) tissue groups are char-
acterized with their volumes (Table 1), perfusion
rates (QF, QRT, QST, and QL), partition coefﬁcients
(Pf, PRT, PST, and PL), and concentrations of
venous blood effluents (CVF, CVRT, CVST, and
CVL). CV is the mixed venous blood concentration,
QC and QP are cardiac output and pulmonary ven-
tilation, and CI and CX are inhaled and exhaled air
concentrations. 
H
Cl Cl
Cl
SG
Cl Cl
H S
Cl Cl
H NH
3+
H
COO-
S
Cl Cl
H NHCOCH
3
H
COOH
CCl
3 H
OH
OH
Fe
O
Cl
H C
+
Cl
Cl
O gluc
CCl3
OH
Cl2CH
O
OH
Cl3C
O
SG
H Cl
Cl S
H Cl
Cl NH
3+
H
COO-
S
H Cl
Cl NHCOCH
3
H
COOH
CCS
Cl
H SH
Cl Cl
H
H
Cl
2HC
S
O H CCl3
Thioketene
S-1,2-DCVC
CYP450
CYP450
TCOH TCOG
DCA TCA
CHO
S-1,1-DCVC
GSH
GSH
β-Lyase
β-Lyase
Cytotoxicity
Mutagenicity
Cytotoxicity
Mutagenicity
1,2-DVT
Excretion
in Urine
Excretion
in Urine
Lung
Fat
Richly
perfused
tissue
Slowly
perfused
tissue
Liver
TCE
MC
PERC
CVL QL, PL
CVST QST, PST
CVRT QRT, PRT
CVF QF, PF
CV QC
CI,CX QPthe three solvents. We used the mixture model
to evaluate the general pharmacokinetic pro-
ﬁle of two common biomarkers of exposure,
peak TCE blood concentrations and total
amount of TCE metabolites generated, in rats
and humans. We then used PBPK models for
each single chemical and the integrated mix-
ture model to calculate interaction thresholds
for both species for a variety of occupationally
relevant exposure scenarios. Finally, we calcu-
lated the relative changes in each biomarker of
exposure at the simulated interaction thresh-
olds in humans.
PBPK model development and parame-
terization. The kinetics of each solvent in the
chemical mixture are described by individual
PBPK models, linked via the metabolism term
in the liver compartment (Andersen et al.
1987). The human body is represented as a
system of ﬁve tissue compartments (liver, adi-
pose, lung, and richly and slowly perfused tis-
sue groups) connected through the systemic
blood circulation (Figure 2). Physiologic,
physicochemical, and biochemical model
parameters originate from the literature and
are summarized in Tables 1 and 2 (Dobrev et
al. 2001; Fisher et al. 1998; Gargas et al.
1986; Reitz et al. 1988, 1996). The solvents
enter the body via inhalation, and their uptake
in each tissue compartment is assumed to be
blood-flow limited. Metabolism is restricted
to the liver and includes oxidative cytochrome
P450 (CYP450)-mediated pathway (a sat-
urable Michaelis-Menten process) and a ﬁrst-
order elimination process describing the GSH
conjugation of TCE (Figure 1). Competitive
inhibition is incorporated into the saturable
metabolism term of each chemical to account
for the coexposure effects of the other two
mixture components as described for the rat
(Dobrev et al. 2001). However, because of
limitations in detecting possible changes in
PERC and MC metabolism caused by TCE
coexposure, only inhibition of TCE metabo-
lism was implemented through the use of
appropriate inhibition constants (i.e., Ki =
100,000 for PERC and MC). Parameterization
of the GST-mediated pathway was from the
work of Clewell et al. (2000) and includes a
first-order process for production of both
S-1,2- and S-2,2-DCVC isomers in the liver.
The rate constant for DCVC generation (K;
Table 2) in the Clewell et al. model is esti-
mated from measurements of oxidative and
conjugative metabolites in urine of human
volunteers after TCE exposures (Bernauer et
al. 1996). In its present form, the mixture
model accounts for changes in DCVC pro-
duction rates of potentially cytotoxic/geno-
toxic metabolites; however, further activation
and/or detoxification processes are not
included (Clewell et al. 2000). Because rates
for GSH conjugation of TCE in humans are
reported to be 1,000–7,000 times lower than
the oxidative rates of metabolism (Bloemen et
al. 2001), the calculation of total metabolites
generated as an indication for occurrence of
metabolic interactions was based only on the
saturable oxidative pathway (see “Results and
Discussion”).
Allometric scaling was applied to rates of
metabolism (Vmax, K), cardiac output (QC),
and pulmonary ventilation (QP) to account
for differences in body weight (Krishnan et al.
1994a). Apparent afﬁnity constants (Km) and
inhibition constants (Ki) are considered
enzyme-speciﬁc parameters and used with no
modification. Model differential equations
(provided in Appendix) are solved using
ACSL (Advanced Continuous Simulation
Language) version 11.5 (AEgis Simulation,
Inc., Huntsville, AL) and Berkeley Madonna
(Berkeley, CA) simulation software packages.
Individual model calibration. Our human
mixture model integrates previously devel-
oped, validated, and extensively studied indi-
vidual PBPK models for TCE, PERC, and
MC. The performance and potential limita-
tions of these single chemical models are dis-
cussed elsewhere (Fisher 2000; Reitz et al.
1988, 1996). Because parameterization of our
mixture model originates from formerly vali-
dated human models, no experimental veriﬁ-
cation of either the model parameters or the
single-model simulations described in the lit-
erature source was undertaken in this study.
Instead, we used available literature data on
human exposures to each single chemical to
evaluate the overall performance of the indi-
vidual PBPK models (Fernandez et al. 1976;
Fisher et al. 1998; Monster et al. 1979; Reitz
et al. 1988). From a variety of published
data, we selected parent compound blood
and expired air concentrations as direct and
sensitive descriptors of the chemicals’ phar-
macokinetics. Good agreement between sin-
gle-model simulations and kinetic data from
four different laboratories covering the period
1976–1998 was achieved without further sta-
tistical optimization (Figures 3–5). We per-
formed model calculations for the exposure
conditions specified in each particular work
and a standard body weight of 70 kg. 
Interaction threshold calculations.
Inhibitors will cause some changes in the sub-
strate’s kinetics at any exposure level.
However, inhibition at very low concentra-
tions will not be quantitatively signiﬁcant. We
deﬁned the interaction threshold as the mini-
mal level of change in the tissue dosimetry
Articles • Risk assessment of chemical mixtures
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Table 2. Partition coefﬁcients and biochemical constants for rats and humans used in the ternary-mixture
PBPK model.
TCE PERC MC
Humana Ratb Humanc Ratb Humand Ratd
Partition coefﬁcients
Blood/air 11.2 22.0 10.3 18.9 2.5 5.8
Fat/blood 52.3 25.3 119.1 86.9 104.0 45.7
Liver/blood 4.9 1.2 5.9 3.7 3.4 1.5
Richly perfused tissue/blood 1.1 —e 5.9 —e 3.4 —e
Slowly perfused tissue/blood 1.4 —e 3.1 —e 0.6 —e
Lumped tissue/air —e 0.5 —e 1.1 —e 0.6
Biochemical constants
Vmax (mg/hr/kg) 4.0 11.0 1.42 0.93 0.42 0.42
Km (mg/L) 1.80 0.25 4.66 5.62 5.75 5.75
Ki (mg/L)f —g —g 6.3 6.3 4.2 4.2
K (hr) 0.015h
aFisher et al. 1998. bGargas et al. (1986). cCalculated from Reitz et al. (1996). dReitz et al., 1988. eRat PBPK model uses
three-compartment structure [see Dobrev et al. (2001)]. fDobrev et al. (2001; rat estimates). gInhibition effect of TCE on
PERC and MC metabolism (Dobrev et al. 2001). hClewell et al. 2000.
Table 1. Physiologic parameters for rats and humans used in the ternary-mixture PBPK model.
Physiologic parameters Human Rat
Alveolar ventilation (L/hr/kg) 15.0 15.0
Cardiac output (L/hr/kg) 15.0 15.0
Blood ﬂow as a fraction of total cardiac output
Blood ﬂow to liver 0.25 0.25
Blood ﬂow to richly perfused tissue 0.449 —a
Blood ﬂow to slowly perfused tissue 0.249 —a
Blood ﬂow to fat 0.052 0.09
Blood ﬂow to lumped tissue —a 0.66
Compartment volumes as fraction of body weight
Fraction slowly perfused 0.651 —a
Fraction richly perfused 0.118 —a
Fraction fat 0.214 0.09
Fraction liver 0.026 0.04
Fraction lumped tissue —a 0.78
aRat PBPK model uses a three-compartment structure (Dobrev et al. 2001).associated with potentially adverse health
effects (Dobrev et al. 2001; El-Masri et al.
1996a, 1996b). A 10% or more increase in
TCE blood concentration or a 10% or more
decrease of the total TCE metabolites gener-
ated as a direct result of mixture coexposure
was proposed as a criterion for the occurrence
of chemical interaction (Dobrev et al. 2001).
The selected level of alteration (10%) illus-
trates a potential application of our modeling
approach and can be easily changed for any
particular purpose. We performed model
simulations using two mechanistic models
(competitive inhibition and no interaction)
for constant exposures of rats and humans to
different solvent levels and combinations.
Comparing the output of the two mechanis-
tic models at the end of the 6-hr exposure
period allowed calculation of the interaction
thresholds.
Results
Using the integrated human mixture model,
we investigated the pharmacokinetic proﬁles
of two common biomarkers of exposure, peak
TCE blood levels and total amount of TCE
metabolites generated, over a broad range of
PERC and MC coexposure concentrations. In
addition, we used changes in the production
rates of metabolites formed by GSH conjuga-
tion to quantitatively assess the impact of
increased TCE blood concentrations on the
potential metabolic shift toward this generally
minor biotransformation pathway.
In each simulated experiment, calcula-
tions were performed for a constant 6-hr
occupational TLV exposure to TCE (50
ppm) and gradually increasing PERC and
MC concentrations (up to 2,000 ppm). The
results at the end of the 6-hr exposure period
are summarized as dose–response surface
plots in Figures 6–8 and illustrate the general
pharmacokinetic behavior of these dose mea-
sures within the investigated concentration
range. The simulated peak TCE blood level
at the end of a single chemical exposure to 50
ppm was 1.29 mg/L; this value would
increase to 1.83 mg/L (a 42% change) during
the coexposure concentrations of PERC and
MC up to 2,000 ppm (Figure 6). The maxi-
mal change in this biomarker (i.e., assuming
complete inhibition of TCE metabolism) was
calculated at 1.92 mg/L (49% increase), and
this value was not reached in simulated expo-
sures up to 20,000 ppm of PERC and MC
(1.91 mg/L; data not shown).
The change in the total TCE metabolites
generated followed a similar pattern, although
in the opposite direction: suppression of TCE
metabolism due to mixture coexposure logi-
cally resulted in decreased metabolite forma-
tion (Figure 7). Starting at 166.4 mg total
metabolites [2.4 mg/kg body weight (BW)]
for exposure to TCE alone, this biomarker
would decrease to 26.8 mg (0.38 mg/kg BW)
at PERC and MC coexposure concentrations
of 2,000 ppm. This fractional change of 84%
(vs. single TCE exposure) is considerably
higher than the observed increase in parent
compound blood concentration, indicating a
better sensitivity of metabolite generation to
detect chemical interactions. As demonstrated
with the peak blood levels, simulations at very
high coexposure levels of PERC and MC (up
to 20,000 ppm) did not completely inhibit
TCE metabolism (data not shown).
Model output for the expected changes in
the amount of DCVC metabolites is summa-
rized in Figure 8. For a single chemical expo-
sure to 50 ppm TCE, the model predicted
generation of 64 µg (0.9 µg/kg BW) DCVC
derivatives at the end of the 6-hr exposure
period. This amount is approximately 3,000
times less than the simulated total oxidative
TCE metabolites for the same exposure condi-
tions (166 mg; Figure 7) and is in general
agreement with the reported quantitative dif-
ferences in both metabolic pathways (Bloemen
Articles • Dobrev et al.
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Figure 3. Evaluation of the single PERC PBPK model performance: model simulations versus literature
data. (A) PERC concentration in exhaled air, after exposure to 200 ppm for 8, 6, 4, and 2 hr (Fernandez et al.
1976). (B) Venous blood concentration during and after 4-hr exposures to 72 and 144 ppm PERC with and
without workload (Monster et al. 1979). Symbols are measured data, and lines are model simulations.
Figure 4. Evaluation of the single 1,1,1-trichloroethane PBPK model performance: model simulations ver-
sus literature data (Reitz et al. 1988). MC concentration in exhaled air (A) and venous blood (B) during and
after 6-hr exposure to 35 and 350 ppm MC. Symbols are measured data, and lines are model simulations.
Figure 5. Evaluation of the single TCE PBPK model performance: model simulations versus literature data
(Fisher et al. 1998). TCE concentration in exhaled air [(A) 4-hr exposure to 100 ppm] and venous blood [(B)
4-hr exposure to 50 ppm]. Different symbols are measured data in different subjects, and lines are model
simulations.
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netic profile of the oxidative metabolites
(Figure 7), inhibition of TCE metabolism in
the presence of PERC and MC significantly
increased the total DCVC products (Figure
8). Such an increase is directly related to the
elevated blood levels of the parent chemical
(Figure 6), and for coexposure concentrations
of 1,000 ppm PERC and MC, the amount of
DCVC metabolites increased more than
64%, reaching 105 µg (1.5 µg/kg BW).
Under the hypothetical conditions of com-
plete metabolic inhibition (i.e., lack of oxida-
tive TCE metabolism), the upper limit for
DCVC metabolite generation was calculated
at 121 µg (1.7 µg/kg BW).
With respect to the practical application
of our work to biological monitoring of occu-
pational exposures, we calculated interaction
thresholds in rats and humans using TCE
blood levels and total TCE metabolites as bio-
markers of combined exposures to the three
solvents. Modeling results for selected occupa-
tionally relevant exposures to TCE in combi-
nation with PERC and/or MC (implementing
no-interaction and competitive-inhibition
mechanistic models) and the calculated inter-
action thresholds in humans are summarized
in Table 3. Using our previously reported mix-
ture model (Dobrev et al. 2001), interaction
thresholds in rats were calculated for compara-
ble exposure scenarios (Table 4). Simulated
TLV exposures to the three solvents (i.e.,
25/50/350 ppm of PERC/TCE/MC) pre-
dicted a 15% (human) and 22% (rat) increase
in the peak TCE blood concentration, and a
29% (human) and 6% (rat) decrease in the
total TCE metabolites generated compared
with single chemical exposures. Binary TLV
exposures to TCE/PERC mixtures did not sig-
nificantly affect any biomarker in either
species, whereas interaction thresholds for
human TCE/MC exposures were reached at
50 ppm TCE and 230 ppm MC (TCE blood
levels), and 50 ppm TCE and 100 ppm MC
(total TCE metabolites), respectively.
Keeping TCE and PERC concentrations at
their current TLV/TWA levels, interaction
thresholds in humans for the ternary mixture of
TCE/MC/PERC were calculated at 50/180/25
ppm (TCE blood levels) and 50/65/25 ppm
(total TCE metabolites), respectively (Table 3).
Under the same exposure conditions, interac-
tion thresholds in rats were calculated at
50/130/25 ppm TCE/MC/PERC using TCE
blood levels as a biomarker of exposure (Table
4). The change in total TCE metabolites pre-
dicted by the rat model did not exceed the
10% signiﬁcance level within the selected TLV
evaluation range.
Discussion
Our laboratory has been practicing “in silico”
experimentation for about 10 years. In
essence, it means integrating computer mod-
eling with focused, mechanistic, animal
experimentation such that experiments that
are impractical (e.g., too large, too expensive)
or impossible (e.g., human experiments with
carcinogens) to perform are conducted on
computer. Earlier examples of in silico experi-
mentation from our laboratory, using
PBPK/pharmacodynamic modeling and other
computer modeling techniques such as
Monte Carlo simulation, include a) acute
toxicity studies, at 1,000 rats per group, of
toxicologic interactions between Kepone and
carbon tetrachloride (El-Masri et al. 1996c);
b) human biological exposure index studies
on six industrial solvents (Thomas et al.
1996a); c) interaction threshold studies on
binary and ternary chemical mixtures
(Dobrev et al. 2001; El-Masri et al 1996a,
1996b); d) studies on age- and dosing-related
pharmacokinetic changes in mice in a 2-year
chronic toxicity/carcinogenicity bioassay
(Thomas et al. 1996b); and e) clonal growth
modeling of early stages of carcinogenesis
(Ou et al. 2001, 2002). We believe that use
of computer simulation is essential in the
studies of chemical mixture toxicology and
risk assessment. The area of toxicology, in
general, will be well served by the application
of computer technology as an alternative
research method to minimize the killing of
laboratory animals.
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Figure 7. Pharmacokinetic proﬁle of total TCE metabolites generated in humans at the end of a constant 6-
hr TLV exposure (50 ppm) to TCE for various PERC and MC concentrations.
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Figure 6. Pharmacokinetic proﬁle of peak TCE blood concentration in humans at the end of a constant 6-hr
TLV exposure (50 ppm) to TCE for various PERC and MC concentrations.Combined exposures to multiple chemi-
cals have been shown to signiﬁcantly affect the
pharmacokinetics of one or more mixture
components and alter the target tissue dose
(Andersen et al. 1987; El-Masri et al. 1996a,
1996b; Pelekis and Krishnan 1997; Tardif
and Charest-Tardif 1999; Tardif et al. 1993,
1995). A previously reported rat study from
our laboratory indicated that occupational
exposures to chemical mixtures of the three
solvents within their TLV/TWA limits would
result in a significant increase (22%) in the
TCE blood levels compared with single chem-
ical exposures (Dobrev et al. 2001). In the
present study, we have developed and imple-
mented an integrated human PBPK model to
assess the significance of these findings for
human occupational exposures to TCE,
PERC, and MC. Our calculations show that
simulated TLV exposures to TCE, PERC,
and MC (50, 25, and 350 ppm, respectively)
are expected to produce a 15% increase of the
TCE blood concentration compared with sin-
gle chemical exposure (Table 3; 1.48 vs. 1.29
mg/L). The health signiﬁcance of such eleva-
tion in TCE dose might become even more
important with respect to the presence of the
other two solvents in the chemical mixture,
which have similar sedative effects on the cen-
tral nervous system (and are expected to be
additive at low doses). Currently, exposures to
mixtures of organic solvents are usually calcu-
lated as cumulative exposure indices (CEIs) by
adding the ratios of biological monitoring
results to the respective BLVs (Jang et al.
1999b, 2001). As shown here, CEIs devel-
oped without considering possible pharma-
cokinetic interactions may significantly
underestimate exposure. Therefore, it is espe-
cially important to review the BLVs of organic
solvents concerning their metabolic interac-
tions (Jang et al. 2001). If exposure to one
chemical is unlikely, and coexposure is com-
mon in most occupational exposures, meta-
bolic interactions should be considered in
applying and developing BLVs.
Long-term health effects of TCE, on the
other hand, are clearly associated with its bio-
transformation products (Barton and Clewell
2000; Bull 2000; Lash et al. 2000). Hence, a
detailed understanding and quantitative
assessment of the changes in TCE metabo-
lism in chemical mixtures become particularly
important for the risk assessment of chronic
exposures to this solvent. Of oxidative and
conjugative biotransformation products
(Figure 1), genotoxic and nephrotoxic
DCVC isomers appear to be the most rele-
vant for the recorded chronic toxicity of
TCE. In a recently reported study, an
increased incidence of renal tumors was
observed in a cohort of workers occupation-
ally exposed to high TCE concentrations for
more than 20 years (Henschler et al. 1995).
The slow excretion rate of these metabolites is
likely to result in a more important contribu-
tion of this generally minor pathway in TCE
and PERC metabolism, especially with long-
term occupational exposures. In addition,
some nonlinearities in the conjugative bio-
transformation of PERC observed in rats,
nonevident in TCE metabolism (Bernauer et
al. 1996), may become more prominent at
conditions inhibiting the CYP450 oxidative
pathway. Therefore, pharmacokinetic factors
that increase the ﬂux through this metabolic
pathway could substantially contribute to sig-
niﬁcantly increased risk of kidney tumor for-
mation in exposed populations. Recent work
on a five component chemical mixture pre-
dicted up to 4-fold increases in cancer risk for
combined exposures to dichloromethane due
to increased metabolic ﬂux through the GSH
conjugation pathway (Haddad et al. 2001).
Our results further exemplify the impor-
tance of such analysis for risk assessment of
chemical mixtures. Elevated TCE blood lev-
els, as a result of multiple exposures, will
consequently lead to higher TCE bioavail-
ability for GSH conjugation. In general, the
pharmacokinetic profile of DCVC metabo-
lites follows the pattern demonstrated for the
change in the TCE blood levels for mixed
exposures (Figures 6 and 8). Such pharmaco-
kinetic behavior can be logically expected,
because the model structure links linearly the
production rates of DCVC to the liver
concentration of TCE (Clewell et al. 2000).
However, TCE blood levels in the liver are
nonlinearly correlated to saturable Michaelis-
Menten kinetics of the quantitatively pre-
dominant oxidative TCE metabolism. Thus,
Articles • Dobrev et al.
1036 VOLUME 110 | NUMBER 10 | October 2002 • Environmental Health Perspectives
Table 3. Interaction thresholds in humans for occupationally relevant exposures to TCE, MC, and PERC. 
Exposure level (ppm) TCE blood conc (mg/L) Total TCE metabolites (mg)
TCE MC PERC Comp inhibition No interaction Comp inhibition No interaction
50 350 0 1.46 1.29 120.84 166.42
50 300 0 1.44 1.29 130.86 166.42
50* 230* 0* 1.42* 1.29* 125.64 166.42
50 130 0 1.37 1.29 145.59 166.42
50* 100* 0* 1.35 1.29 149.87* 166.42*
50 350 25 1.48 1.29 117.49 166.42
50 250 25 1.44 1.29 126.88 166.42
50* 180* 25* 1.42* 1.29* 135.06 166.42
50 130 25 1.39 1.29 140.55 166.42
50 100 25 1.37 1.29 144.48 166.42
50* 65* 25* 1.36* 1.29 149.40* 166.42*
50 0 25 1.32 1.29 159.58 166.42
Abbreviations: comp, competitive; conc, concentration. The simulated exposure and biomarker levels at which a signiﬁ-
cant metabolic interaction is likely to occur are highlighted. “No interaction” values are calculated for single TCE expo-
sures using the mixture model (MC and PERC concentrations are zero).
*Interaction thresholds.
Figure 8. Pharmacokinetic proﬁle of total DCVC metabolites generated in humans at the end of a constant
6-hr TLV exposure (50 ppm) to TCE for various PERC and MC concentrations.
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0 0a fractional change in the TCE blood concen-
tration of 15% for combined TLV exposure
to the three chemicals (25/50/350 ppm of
PERC/TCE/MC) results in a 27% increase
of the DCVC metabolites (Table 5).
Similarly, binary combinations of the solvents
produced GST-mediated metabolite levels
almost twice as high as the expected rates of
increase in the parent compound blood levels
(Table 5). Further comparison with the simu-
lated interaction thresholds in humans (Table
5) indicates 17–18% increased DCVC prod-
ucts at the 10% signiﬁcance level using TCE
blood concentration as a biomarker of expo-
sure. In the same time, the simulated increase
of DCVC metabolites remained 9% for inter-
action thresholds derived from total TCE
metabolites as a biomarker of exposure
(Table 5). Such differences illustrate the
importance of selecting appropriate biomark-
ers of exposure in the risk assessment of
chemical mixtures.
Biomarkers of exposure, such as reduced
metabolite generation and/or increased blood
concentration of the parent compound, are
widely used dose measures for identifying
pharmacokinetic interactions during and
after exposure to chemical mixtures. Recent
work demonstrated the differential sensitivity
of each biomarker toward detection of meta-
bolic interactions and its application to
research involving chemical mixtures (Tardif
and Charest-Tardif 1999). Experimental
data and pharmacokinetic analysis at steady
state illustrated that combined exposures to
MC and m-xylene did not affect MC blood
levels but signiﬁcantly reduced the formation
and excretion of two MC metabolites,
TCOH and trichloroacetic acid (Tardif and
Charest-Tardif 1999). Therefore, one of the
objectives of our study was to evaluate these
two biomarkers of exposure, namely, TCE
blood levels and total TCE metabolite for-
mation, as appropriate measures for occur-
rence of pharmacokinetic interactions in
occupational settings.
For the selected mixture, both dose metrics
can be used as biomarkers of chemical interac-
tion. At a 10% signiﬁcance level, earlier detec-
tion of interaction thresholds (i.e., at lower
exposure levels) would be possible based on
decreased TCE metabolite formation as a bio-
marker of exposure rather than using parent
compound levels (Table 3). Our approach
illustrates the importance of investigating and
selecting the appropriate dose measure in the
overall process of risk assessment for these mix-
tures. Particularly, the difference in the
estimated 10% interaction threshold for MC
coexposure is 65 versus 180 ppm in ternary
and 100 versus 230 ppm in binary mixtures,
depending on the biomarker used (Table 3).
Choosing the less sensitive biomarker (parent
blood levels in this case) would result in two to
three times higher estimates of potentially safe
exposure levels. In addition, assuming DCVC
metabolite generation as the main adverse
health effect for long-term TCE exposures,
interaction thresholds based on total TCE
metabolites will be more appropriate, because
quantitatively they correspond more closely
with the expected changes in DCVC produc-
tion rates (Table 5). For instance, interaction
thresholds (i.e., solvent concentrations in air)
calculated using a 10% increase in parent TCE
blood levels would correspond to an 18% rise
in DCVC formation (roughly twice the prese-
lected threshold level of 10%), whereas inter-
action thresholds based on a 10% decrease in
total TCE metabolites correspond to a 9%
increase in DCVC metabolites.
In the course of this study, important
species-speciﬁc differences became evident. In
rats, TCE blood concentration is the more
sensitive parameter to detect the metabolic
inhibition effects of PERC and MC (Figure
9), whereas in humans the total of TCE
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Table 4. Interaction thresholds in rats for occupationally relevant exposures to TCE, MC, and PERC. 
Exposure level (ppm) TCE blood conc (mg/L) Total TCE metabolites (mg)
TCE MC PERC Comp inhibition No. interaction Comp inhibition No interaction
50 350 0 1.20 1.00 6.57 6.93
50 300 0 1.17 1.00 6.61 6.93
50 200 0 1.12 1.00 6.72 6.93
50* 170* 0* 1.10* 1.00* 6.75 6.93
50 100 0 1.06 1.00 6.82 6.93
50 350 25 1.22 1.00 6.53 6.93
50 250 25 1.17 1.00 6.63 6.93
50 180 25 1.13 1.00 6.70 6.93
50* 130* 25* 1.10* 1.00* 6.75 6.93
50 65 25 1.06 1.00 6.82 6.93
50 0 25 1.02 1.00 6.89 6.93
Abbreviations: comp, competitive; conc, concentration. The simulated exposure and biomarker levels at which a signiﬁ-
cant metabolic interaction is likely to occur are highlighted. “No. interaction” values are calculated for single TCE expo-
sures using the mixture model (MC and PARC concentrations are zero). A 10% interaction threshold based on total TCE
metabolites generated would be reached at 6.24 mg.
*Interaction thresholds.
Table 5. Increased generation of toxic GSH metabolites (compared with single-chemical exposure) for
combinations of binary and ternary TLV exposures to TCE, PERC, and MC, and their relation to the calcu-
lated interaction thresholds in humans.
Exposure level (ppm) TCE blood conc CYP450 metabolites GSH metabolites
TCE MC PERC (mg/L) (mg) (µg)
50 0 0 1.29 166.42 62.4
50 350 25 1.48 (15%) 117.49 (29%) 79.0 (27%)
50 350 0 1.46 (13%) 120.84 (27%) 77.7 (24%)
50 0 25 1.32 (2%) 159.58 (4%) 64.8 (4%)
50* 230* 0* 1.42* 125.64 73.5 (18%)
50* 100* 0* 1.35 149.87* 67.9 (9%)
50* 180* 25* 1.42* 135.06 73.2 (17%)
50* 65* 25* 1.36 149.40* 68.2 (9%)
conc, concentration. The simulated exposures at which a signiﬁcant metabolic interaction is likely to occur and the cor-
responding biomarker levels are highlighted. Values in parenthesis indicate a fractional change in the biomarker levels
and GSH metabolites. See “Discussion” for more details.
*Interaction thresholds.
Figure 9. Evaluation of TCE blood concentration at
the end of a constant 6-hr TLV exposure (50 ppm) to
TCE as a biomarker for the occurrence of chemical
interactions in binary and ternary mixture combina-
tions of TCE, PERC, and MC in (A) human and (B) rat.
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concentration in air (ppm)metabolites produced is a more sensitive dose
measure (Figure 10). The bases for such dis-
crepancies are species differences in physiol-
ogy and/or the chemical-speciﬁc properties of
TCE. The blood/air partition coefficient of
TCE in rats is two times higher than in
humans (22 vs. 11; Table 2), and the rate of
metabolism is three times higher in rats than
in humans (11 vs. 4 mg/hr/kg; Table 2). In
addition, physiologic differences in perfusion
and ventilation rates, as well as the size of fat
and liver compartments, may play an impor-
tant role in the observed phenomenon. These
factors were readily evaluated by in silico sim-
ulation with the PBPK model.
Generally, interaction thresholds in
humans exposed to ternary mixtures of TCE,
PERC, and MC are expected to occur at lower
exposure concentrations than in rats (Figures 9
and 10). Toxicologically, the consequences of
the observed shifts toward lower metabolite
and higher parent compound concentrations
in blood remain to be investigated. Elevated
TCE blood concentrations are clearly associ-
ated with suppression of the central nervous
system. During combined exposures, such
effects are expected to occur at lower exposure
levels compared with single TCE exposure. In
addition, changes in the metabolism pattern
will lead to higher bioavailability of TCE for
the GSH metabolic pathway, resulting in
higher risk of kidney damage.
Our results exemplify the a priori use of
PBPK modeling for designing interaction stud-
ies and identifying sensitive end points.
Further, interactive model exercises will allow
estimation of safe exposure levels during multi-
ple chemical exposures. The approach illus-
trates a novel application of PBPK modeling to
predict the occurrence of metabolic interactions
during mixed exposures and quantitatively
Articles • Dobrev et al.
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Figure 10. Evaluation of total TCE metabolites gen-
erated at the end of a constant 6-hr TLV exposure
to TCE as a biomarker for the occurrence of chemi-
cal interactions in ternary mixtures of TCE, PERC,
and MC in (A) human and (B) rat.
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Appendix
A series of mass balance differential equa-
tions were used to build the ternary mixture
PBPK model. For each compartment, an
equation describes the uptake, metabolism
(in liver only), and elimination for each of
the three mixture components. Uptake in
each nonmetabolizing tissue group (fat,
slowly and richly perfused compartments) is
a blood-flow-limited process governed by
the perfusion rate of the particular compart-
ment (QT, as L/hr), the tissue/blood parti-
tion coefficient (PT), and the arterial
concentration (CA, as mg/L):
[1]
Here, CT is each chemical’s concentration
(mg/L) in a nonmetabolizing tissue com-
partment with volume VT (L).
Metabolism occurs in the liver using an
additional term to account for the rate of
change in the metabolized amount, 
added to Equation 1:
[2]
Metabolism of TCE, PERC, and MC in
the liver follows saturable Michaelis-Menten
kinetics. Assuming competitive inhibition as
the predominant mechanism of pharmaco-
kinetic interaction related to combined
exposures (Andersen et al. 1987), the rate of
saturable metabolism 
for each solvent is given by
[3]
Subscripts 1, 2, and 3 indicate parame-
ters related to compounds 1, 2, and 3 in the
chemical mixture. Vmax (mg/hr/kg) and Km
(mg/L) are the maximum rate of metabo-
lism and the apparent affinity constant,
respectively: KI is the inhibition constant
(mg/L), and PL is the liver/blood partition
coefﬁcient for each component.
For TCE, the production rate of GST-
mediated DCVC metabolites,
is calculated as the product of a first-order
rate constant K (/hr), the liver volume VL
(L), and the TCE concentration in the liver
(CL, mg/L):
[4]
Accordingly, the total mass balance of
TCE in the liver is
[5]
The concentration CA (mg/L) of each
solvent in the arterial blood leaving the lung
compartment depends on pulmonary
ventilation (QP) and cardiac output (QC)
rates, the venous blood concentration (CV)
entering the lungs, the blood/air partition
coefficient (PB), and the atmospheric con-
centration Cair (mg/L):
[6]
The venous blood effluents Q × CV of
all tissue compartments combine to yield
the ﬂow-averaged mixed venous concentra-
tion, CV, of each solvent:
[7]
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d
–.assess their impact on the kinetics of each indi-
vidual mixture component. The nonlinear rela-
tionships of total GSH metabolites and TCE
blood concentration and human/animal differ-
ences in response to these mixtures are impor-
tant predictions that should be evaluated by
appropriate experimentation.
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